The life-threatening and progressive nature of PNH warrants early identification in high-risk patient populations
Evaluate high-risk patients with the PNH Diagnosis Pathway; the current availability of an effective PNH treatment option warrants testing appropriate patients
The life-threatening and destructive consequences of hemolysis (as measured by LDH) warrant early identification in high-risk subpopulations
Chronic hemolysis is the underlying cause of progressive morbidities and mortality in PNH2; therefore, reducing chronic hemolysis is the primary goal of PNH treatment. Early identification of PNH in high-risk populations is optimal for long-term disease management. Use the PNH Diagnostic Pathway displayed above to help identify those patients in your practice who may be at risk for PNH.
Click on the following links for more information regarding diagnosis in populations at high risk for PNH:
